WASHINGTON, D.C. – October 31, 2013 – A leading cause of heart disease remains overlooked in North America’s most impoverished communities, researchers said today in an editorial published in PLOS Neglected Tropical Diseases. Chagas disease has rendered a heavy health and economic toll, yet insufficient political and medical support for gathering specific data, providing diagnosis and treatment, and developing new tools have impeded much-needed breakthroughs.
WASHINGTON, DC – October 21, 2013 – The Sabin Vaccine Institute today announced the election to its Board of Trustees of Michael H. Posner, Professor of Business and Society at New York University’s Stern School of Business. For more than three decades, Mr. Posner has advanced the causes of inclusive global human rights, dignity, freedom and justice.
AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people. Under this grant, the HOOKVAC consortium, which includes partners from the European Union, United States and Africa, will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.
Sabin Vaccine Institute convoque des représentants des gouvernements pour